Interaction between Atropine and Hexobarbital in the Abstinence after Chronic Barbital Treatments in the Rat

  • G. Wahlstrom
  • A. Nordberg
Part of the Advances in Behavioral Biology book series (ABBI, volume 25)


After chronic treatments with barbital a decreased sensitivity to hexobarbital can be observed in rats. Such a decreased sensitivity is usually called tolerance and it can be detected for at least 60 days after the end of a 50 week long barbital treatment (8). There is a positive relation between the duration of the treatment and the duration of the tolerance found in the abstinence (2). Spontaneous convulsions during abstinence are usually regarded as a sign that physical dependence has been induced by the treatment. The frequency of the spontaneous convulsions also seems to depend on the duration of barbital treatment and can be recorded at least for the first five weeks of abstinence after 50 weeks of barbital treatment (8). Since convulsions can decrease tolerance to hexobarbital a relation seems to exist between these two variables (3). Thus, long term treatments with barbital can induce changes in the CNS indicating increased escitation which lasts for a long time during the abstinence. Several changes in brain cholinergic mechanisms, indicating increased activity, have also been found during abstinence (Nordberg and Wahlstrom, this volume) and these changes might be related to the tolerance and physical dependence described above (6).


Lasting Effect Brain Weight Physical Dependence Cholinergic Activity Cholinergic Mechanism 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Wahlstrom G. (1966): Acta Pharmacol. Toxicol. 24:404–418.CrossRefGoogle Scholar
  2. 2.
    Wahlstrom G. (1974): Acta Pharmacol. Toxicol. 35:131–144.CrossRefGoogle Scholar
  3. 3.
    Wahlstrom G. (1976): Life Sci. 19:1817–1826.CrossRefGoogle Scholar
  4. 4.
    Wahlstrom G. (1978): Psychopharmacology 59:123–128.CrossRefGoogle Scholar
  5. 5.
    Wahlstrom G. (1979): Eur. J. Pharmacol. 51:219–227.CrossRefGoogle Scholar
  6. 6.
    Wahlstrom G. (1979): Drug Alcohol Depend. 4:221–230.CrossRefGoogle Scholar
  7. 7.
    Wahlstrom G. (1979): Eur. J. Pharmacol. 59:219–229.CrossRefGoogle Scholar
  8. 8.
    Wahlstrom G. and Larsson, R. (1977): Pharmacol. Biochem. Behav. 6:187–189.CrossRefGoogle Scholar
  9. 9.
    Wahlstrom, G. and Nordberg, A. (1978): Life Sci. 23:1583–1587.CrossRefGoogle Scholar

Copyright information

© Plenum Press, New York 1981

Authors and Affiliations

  • G. Wahlstrom
    • 1
  • A. Nordberg
    • 1
    • 2
  1. 1.Department of PharmacologyUniversity of UmeaUmeaSweden
  2. 2.Department of PharmacologyUniversity of UppsalaUppsalaSweden

Personalised recommendations